Showing papers by "José Luis Zamorano published in 2013"
••
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Abstract: ABCD
: Appropriate Blood pressure Control in Diabetes
ABI
: ankle–brachial index
ABPM
: ambulatory blood pressure monitoring
ACCESS
: Acute Candesartan Cilexetil Therapy in Stroke Survival
ACCOMPLISH
: Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension
ACCORD
: Action to Control Cardiovascular Risk in Diabetes
ACE
: angiotensin-converting enzyme
ACTIVE I
: Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
ADVANCE
: Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation
AHEAD
: Action for HEAlth in Diabetes
ALLHAT
: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack
ALTITUDE
: ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints
ANTIPAF
: ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation
APOLLO
: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
ARB
: angiotensin receptor blocker
ARIC
: Atherosclerosis Risk In Communities
ARR
: aldosterone renin ratio
ASCOT
: Anglo-Scandinavian Cardiac Outcomes Trial
ASCOT-LLA
: Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm
ASTRAL
: Angioplasty and STenting for Renal Artery Lesions
A-V
: atrioventricular
BB
: beta-blocker
BMI
: body mass index
BP
: blood pressure
BSA
: body surface area
CA
: calcium antagonist
CABG
: coronary artery bypass graft
CAPPP
: CAPtopril Prevention Project
CAPRAF
: CAndesartan in the Prevention of Relapsing Atrial Fibrillation
CHD
: coronary heart disease
CHHIPS
: Controlling Hypertension and Hypertension Immediately Post-Stroke
CKD
: chronic kidney disease
CKD-EPI
: Chronic Kidney Disease—EPIdemiology collaboration
CONVINCE
: Controlled ONset Verapamil INvestigation of CV Endpoints
CT
: computed tomography
CV
: cardiovascular
CVD
: cardiovascular disease
D
: diuretic
DASH
: Dietary Approaches to Stop Hypertension
DBP
: diastolic blood pressure
DCCT
: Diabetes Control and Complications Study
DIRECT
: DIabetic REtinopathy Candesartan Trials
DM
: diabetes mellitus
DPP-4
: dipeptidyl peptidase 4
EAS
: European Atherosclerosis Society
EASD
: European Association for the Study of Diabetes
ECG
: electrocardiogram
EF
: ejection fraction
eGFR
: estimated glomerular filtration rate
ELSA
: European Lacidipine Study on Atherosclerosis
ESC
: European Society of Cardiology
ESH
: European Society of Hypertension
ESRD
: end-stage renal disease
EXPLOR
: Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination
FDA
: U.S. Food and Drug Administration
FEVER
: Felodipine EVent Reduction study
GISSI-AF
: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation
HbA1c
: glycated haemoglobin
HBPM
: home blood pressure monitoring
HOPE
: Heart Outcomes Prevention Evaluation
HOT
: Hypertension Optimal Treatment
HRT
: hormone replacement therapy
HT
: hypertension
HYVET
: HYpertension in the Very Elderly Trial
IMT
: intima-media thickness
I-PRESERVE
: Irbesartan in Heart Failure with Preserved Systolic Function
INTERHEART
: Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries
INVEST
: INternational VErapamil SR/T Trandolapril
ISH
: Isolated systolic hypertension
JNC
: Joint National Committee
JUPITER
: Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin
LAVi
: left atrial volume index
LIFE
: Losartan Intervention For Endpoint Reduction in Hypertensives
LV
: left ventricle/left ventricular
LVH
: left ventricular hypertrophy
LVM
: left ventricular mass
MDRD
: Modification of Diet in Renal Disease
MRFIT
: Multiple Risk Factor Intervention Trial
MRI
: magnetic resonance imaging
NORDIL
: The Nordic Diltiazem Intervention study
OC
: oral contraceptive
OD
: organ damage
ONTARGET
: ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
PAD
: peripheral artery disease
PATHS
: Prevention And Treatment of Hypertension Study
PCI
: percutaneous coronary intervention
PPAR
: peroxisome proliferator-activated receptor
PREVEND
: Prevention of REnal and Vascular ENdstage Disease
PROFESS
: Prevention Regimen for Effectively Avoiding Secondary Strokes
PROGRESS
: Perindopril Protection Against Recurrent Stroke Study
PWV
: pulse wave velocity
QALY
: Quality adjusted life years
RAA
: renin-angiotensin-aldosterone
RAS
: renin-angiotensin system
RCT
: randomized controlled trials
RF
: risk factor
ROADMAP
: Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention
SBP
: systolic blood pressure
SCAST
: Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke
SCOPE
: Study on COgnition and Prognosis in the Elderly
SCORE
: Systematic COronary Risk Evaluation
SHEP
: Systolic Hypertension in the Elderly Program
STOP
: Swedish Trials in Old Patients with Hypertension
STOP-2
: The second Swedish Trial in Old Patients with Hypertension
SYSTCHINA
: SYSTolic Hypertension in the Elderly: Chinese trial
SYSTEUR
: SYSTolic Hypertension in Europe
TIA
: transient ischaemic attack
TOHP
: Trials Of Hypertension Prevention
TRANSCEND
: Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease
UKPDS
: United Kingdom Prospective Diabetes Study
VADT
: Veterans' Affairs Diabetes Trial
VALUE
: Valsartan Antihypertensive Long-term Use Evaluation
WHO
: World Health Organization
### 1.1 Principles
The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …
14,173 citations
••
TL;DR: The If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction is evaluated as well as patients with Diabetes mellitus for Optimal management of Multivessel disease.
Abstract: 99mTc
: technetium-99m
201TI
: thallium 201
ABCB1
: ATP-binding cassette sub-family B member 1
ABI
: ankle-brachial index
ACC
: American College of Cardiology
ACCF
: American College of Cardiology Foundation
ACCOMPLISH
: Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
ACE
: angiotensin converting enzyme
ACIP
: Asymptomatic Cardiac Ischaemia Pilot
ACS
: acute coronary syndrome
ADA
: American Diabetes Association
ADP
: adenosine diphosphate
AHA
: American Heart Association
ARB
: angiotensin II receptor antagonist
ART
: Arterial Revascularization Trial
ASCOT
: Anglo-Scandinavian Cardiac Outcomes Trial
ASSERT
: Asymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial
AV
: atrioventricular
BARI 2D
: Bypass Angioplasty Revascularization Investigation 2 Diabetes
BEAUTIFUL
: Morbidity-Mortality Evaluation of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
BIMA
: bilateral internal mammary artery
BMI
: body mass index
BMS
: bare metal stent
BNP
: B-type natriuretic peptide
BP
: blood pressure
b.p.m.
: beats per minute
CABG
: coronary artery bypass graft
CAD
: coronary artery disease
CAPRIE
: Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events
CASS
: Coronary Artery Surgery Study
CCB
: calcium channel blocker
CCS
: Canadian Cardiovascular Society
CFR
: coronary flow reserve
CHARISMA
: Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management and Avoidance
CI
: confidence interval
CKD
: chronic kidney disease
CKD-EPI
: Chronic Kidney Disease Epidemiology Collaboration
CMR
: cardiac magnetic resonance
CORONARY
: The CABG Off or On Pump Revascularization Study
COURAGE
: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
COX-1
: cyclooxygenase-1
COX-2
: cyclooxygenase-2
CPG
: Committee for Practice Guidelines
CT
: computed tomography
CTA
: computed tomography angiography
CV
: cardiovascular
CVD
: cardiovascular disease
CXR
: chest X-ray
CYP2C19*2
: cytochrome P450 2C19
CYP3A
: cytochrome P3A
CYP3A4
: cytochrome P450 3A4
CYP450
: cytochrome P450
DANAMI
: Danish trial in Acute Myocardial Infarction
DAPT
: dual antiplatelet therapy
DBP
: diastolic blood pressure
DECOPI
: Desobstruction Coronaire en Post-Infarctus
DES
: drug-eluting stents
DHP
: dihydropyridine
DSE
: dobutamine stress echocardiography
EACTS
: European Association for Cardiothoracic Surgery
EECP
: enhanced external counterpulsation
EMA
: European Medicines Agency
EASD
: European Association for the Study of Diabetes
ECG
: electrocardiogram
Echo
: echocardiogram
ED
: erectile dysfunction
EF
: ejection fraction
ESC
: European Society of Cardiology
EXCEL
: Evaluation of XIENCE PRIME or XIENCE V vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization
FAME
: Fractional Flow Reserve vs. Angiography for Multivessel Evaluation
FDA
: Food & Drug Administration (USA)
FFR
: fractional flow reserve
FREEDOM
: Design of the Future Revascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease
GFR
: glomerular filtration rate
HbA1c
: glycated haemoglobin
HDL
: high density lipoprotein
HDL-C
: high density lipoprotein cholesterol
HR
: hazard ratio
HRT
: hormone replacement therapy
hs-CRP
: high-sensitivity C-reactive protein
HU
: Hounsfield units
ICA
: invasive coronary angiography
IMA
: internal mammary artery
IONA
: Impact Of Nicorandil in Angina
ISCHEMIA
: International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
IVUS
: intravascular ultrasound
JSAP
: Japanese Stable Angina Pectoris
KATP
: ATP-sensitive potassium channels
LAD
: left anterior descending
LBBB
: left bundle branch block
LIMA
: Left internal mammary artery
LDL
: low density lipoprotein
LDL-C
: low density lipoprotein cholesterol
LM
: left main
LMS
: left main stem
LV
: left ventricular
LVEF
: left ventricular ejection fraction
LVH
: left ventricular hypertrophy
MACE
: major adverse cardiac events
MASS
: Medical, Angioplasty, or Surgery Study
MDRD
: Modification of Diet in Renal Disease
MERLIN
: Metabolic Efficiency with Ranolazine for Less Ischaemia in Non-ST-Elevation Acute Coronary Syndromes
MERLIN-TIMI 36
: Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes: Thrombolysis In Myocardial Infarction
MET
: metabolic equivalents
MI
: myocardial infarction
MICRO-HOPE
: Microalbuminuria, cardiovascular and renal sub-study of the Heart Outcomes Prevention Evaluation study
MPI
: myocardial perfusion imaging
MRI
: magnetic resonance imaging
NO
: nitric oxide
NSAIDs
: non-steroidal anti-inflammatory drugs
NSTE-ACS
: non-ST-elevation acute coronary syndrome
NYHA
: New York Heart Association
OAT
: Occluded Artery Trial
OCT
: optical coherence tomography
OMT
: optimal medical therapy
PAR-1
: protease activated receptor type 1
PCI
: percutaneous coronary intervention
PDE5
: phosphodiesterase type 5
PES
: paclitaxel-eluting stents
PET
: positron emission tomography
PRECOMBAT
: Premier of Randomized Comparison of Bypass Surgery vs. Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease
PTP
: pre-test probability
PUFA
: polyunsaturated fatty acid
PVD
: peripheral vascular disease
QoL
: quality of life
RBBB
: right bundle branch block
REACH
: Reduction of Atherothrombosis for Continued Health
RITA-2
: Second Randomized Intervention Treatment of Angina
ROOBY
: Veterans Affairs Randomized On/Off Bypass
SAPT
: single antiplatelet therapy
SBP
: systolic blood pressure
SCAD
: stable coronary artery disease
SCORE
: Systematic Coronary Risk Evaluation
SCS
: spinal cord stimulation
SES
: sirolimus-eluting stents
SIMA
: single internal mammary artery
SPECT
: single photon emission computed tomography
STICH
: Surgical Treatment for Ischaemic Heart Failure
SWISSI II
: Swiss Interventional Study on Silent Ischaemia Type II
SYNTAX
: SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
TC
: total cholesterol
TENS
: transcutaneous electrical neural stimulation
TERISA
: Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
TIME
: Trial of Invasive vs. Medical therapy
TIMI
: Thrombolysis In Myocardial Infarction
TMR
: transmyocardial laser revascularization
TOAT
: The Open Artery Trial
WOEST
: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing
Guidelines summarize and evaluate all evidence available, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well …
3,879 citations
••
TL;DR: 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy : The Task Force on cardiac paced and resynchronized therapy of the European Society of Cardiology developed in collaboration with the European Heart Rhythm Association.
Abstract: ### Abbreviations
1st AV
: First-degree atrioventricular block
AF
: atrial fibrillation
AT
: atrial tachyarrhythmia
ATP
: Anti-tachycardia pacing
AV
: atrioventricular
BBB
: bundle branch block
CHF
: congestive heart failure
CI
: confidence interval
CPG
: Committee for Practice Guidelines
CRT
: cardiac resynchronization therapy
CRT-D
: cardiac resynchronization therapy and defibrillator
CRT-P
: cardiac resynchronization therapy and pacemaker
ECG
: electrocardiogram
EDMD
: Emery-Dreifuss muscular dystrophy
EF
: ejection fraction
EPS
: electrophysiological study
ESC
: European Society of Cardiology
HCM
: hypertrophic cardiomyopathy
HF
: heart failure
HR
: hazard ratio
HV
: His-ventricular
ICD
: implantable cardioverter defibrillator
ILR
: implantable loop recorder
IVCD
: intraventricular conduction delay
LBBB
: left bundle branch block
LQTS
: long QT syndrome
LV
: left ventricular
LVEF
: left ventricular ejection fraction
LVSD
: left ventricular systolic dysfunction
MR
: mitral regurgitation
MRI
: magnetic resonance imaging
NYHA
: New York Heart Association
PM
: pacemaker
OR
: odds ratio
QALY
: quality-adjusted life year
RBBB
: right bundle branch block
RCT
: randomized controlled trial
RV
: right ventricular
SB
: sinus bradycardia
SNRT
: sinus node recovery time
SR
: sinus rhythm
SSS
: sick sinus syndrome
TAVI
: transcatheter aortic valve implantation
VF
: ventricular fibrillation
VT
: ventricular tachycardia
VV
: interventricular (delay)
### Acronyms of the trials referenced in the recommendations or reported in the tables
ADEPT
: ADvanced Elements of Pacing Randomized Controlled Trial
ADOPT
: Atrial Dynamic Overdrive Pacing Trial
AOPS
: Atrial Overdrive Pacing Study
APAF
: Ablate and Pace in Atrial Fibrillation
ASSERT
: ASymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial
ATTEST
: ATrial Therapy Efficacy and Safety Trial
AVAIL CLS/CRT
: AV Node Ablation with CLS and CRT Pacing Therapies for Treatment of AF trial
B4
: Bradycardia detection in Bundle Branch Block
BELIEVE
: Bi vs. Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias
BIOPACE
: Biventricular pacing for atrioventricular block to prevent cardiac desynchronization
BLOCK-HF
: Biventricular versus right ventricular pacing in patients with AV block
B-LEFT
: Biventricular versus LEFT Univentricular Pacing with ICD Back-up in Heart Failure Patients
CARE-HF
: CArdiac REsynchronization in Heart Failure
CLEAR
: CLinical Evaluation on Advanced Resynchronization
COMBAT
: COnventional vs. Biventricular Pacing in Heart Failure and Bradyarrhythmia
COMPANION
: COmparison of Medical Therapy, Pacing and Defibrillation in Heart Failure
DANPACE
: DANish Multicenter Randomized Trial on Single Lead Atrial PACing vs. Dual Chamber Pacing in Sick Sinus Syndrome
DECREASE-HF
: The Device Evaluation of CONTAK RENEWAL 2 and EASYTRAK 2: Assessment of Safety and Effectiveness in Heart Failure
FREEDOM
: Optimization Study Using the QuickOpt Method
GREATER-EARTH
: Evaluation of Resynchronization Therapy for Heart Failure in Patients with a QRS Duration GREATER Than 120 ms
LESSER-EARTH
: Evaluation of Resynchronization Therapy for Heart Failure in Patients with a QRS Duration Lower Than 120 ms
HOBIPACE
: HOmburg BIventricular PACing Evaluation
IN-CHF
: Italian Network on Congestive Heart Failure
ISSUE
: International Study on Syncope of Unexplained Etiology
MADIT
: Multicenter Automatic Defibrillator Trial
MIRACLE
: Multicenter InSync RAndomized CLinical Evaluation
MOST
: MOde Selection Trial in Sinus-Node Dysfunction
MUSTIC
: MUltisite STimulation In Cardiomyopathies
OPSITE
: Optimal Pacing SITE
PACE
: Pacing to Avoid Cardiac Enlargement
PAVE
: Left Ventricular-Based Cardiac Stimulation Post AV Nodal Ablation Evaluation
PATH-CHF
: PAcing THerapies in Congestive Heart Failure II Study Group
PIPAF
: Pacing In Prevention of Atrial Fibrillation Study
PIRAT
: Prevention of Immediate Reinitiation of Atrial Tachyarrhythmias
POT
: Prevention Or Termination Study
PREVENT-HF
: PREventing VENTricular Dysfunction in Pacemaker Patients Without Advanced Heart Failure
PROSPECT
: PRedictors Of Response to Cardiac Resynchronization Therapy
RAFT
: Resynchronization–Defibrillation for Ambulatory Heart Failure Trial
RethinQ
: Cardiac REsynchronization THerapy IN Patients with Heart Failure and Narrow QRS
REVERSE
: REsynchronization reVErses Remodelling in Systolic left vEntricular dysfunction
SAFARI
: Study of Atrial Fibrillation Reduction
SCD HeFT
: Sudden Cardiac Death in Heart Failure Trial
SMART-AV
: The SMARTDelay Determined AV Optimization: a Comparison with Other AV Delay Methods Used in Cardiac Resynchronization Therapy
SYDIT
: The SYncope DIagnosis and Treatment
SYNPACE
: Vasovagal SYNcope and PACing
TARGET
: TARgeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy
THEOPACE
: Effects of Oral THEOphylline and of Permanent PACEmaker on the Symptoms and Complications of Sick Sinus Syndrome
VASIS-PM
: VAsovagal Syncope International Study on PaceMaker therapy
V-HeFT
: Vasodilator in HEart Failure Trial
VPSII
: Second Vasovagal Pacemaker Study (VPS II)
Additional references are mentioned with ‘w’ in the main text and can be found on the online addenda along with 5 figures (1, 6, 7, 9, 11, 12) and 10 tables (3, 4, 5, 9, 11, 12, 19, 21, 22, 23). They are available on the ESC website only at http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/cardiac-pacing-and-cardiac-resynchronisation-therapy.aspx
Guidelines summarize and evaluate all available evidence, at the time of the writing process, on a …
2,474 citations
••
TL;DR: Authors/Task Force Members, Alec Vahanian (Chairperson) Paris (France)*, Helmut Baumgartner, Vienna (Austria), Jeroen Bax, Leiden (The Netherlands), Eric Butchart, Cardiff (UK), Robert Dion,Leiden ( the Netherlands), Gerasimos Filippatos, Athens (Greece), Frank Flachskampf, Erlangen (Germany).
Abstract: Authors/Task Force Members, Alec Vahanian (Chairperson) Paris (France)*, Helmut Baumgartner, Vienna (Austria), Jeroen Bax, Leiden (The Netherlands), Eric Butchart, Cardiff (UK), Robert Dion, Leiden (The Netherlands), Gerasimos Filippatos, Athens (Greece), Frank Flachskampf, Erlangen (Germany), Roger Hall, Norwich (UK), Bernard Iung, Paris (France), Jaroslaw Kasprzak, Lodz (Poland), Patrick Nataf, Paris (France), Pilar Tornos, Barcelona (Spain), Lucia Torracca, Milan (Italy), Arnold Wenink, Leiden (The Netherlands)
1,369 citations
••
TL;DR: It is crucial to provide standards that aim at establishing a baseline list of measurements to be performed when assessing regurgitation, and to integrate the quantification of the regurgitations, assessment of the valve anatomy and function, as well as the consequences of valvular disease on cardiac chambers.
Abstract: Valvular regurgitation represents an important cause of cardiovascular morbidity and mortality. Echocardiography has become the primary non-invasive imaging method for the evaluation of valvular regurgitation. The echocardiographic assessment of valvular regurgitation should integrate the quantification of the regurgitation, assessment of the valve anatomy and function, as well as the consequences of valvular disease on cardiac chambers. In clinical practice, the management of patients with valvular regurgitation thus largely integrates the results of echocardiography. It is crucial to provide standards that aim at establishing a baseline list of measurements to be performed when assessing regurgitation.
1,263 citations
••
TL;DR: Lékařská fakulta Univerzity Karlovy a Všeobecná fackultní nemocnice, Praha, Česká republika ČESKÁ KARDIOLOGICKÁ SPOLEČNOST the CZECH SOCIETY of CARDIOLOGY.
Abstract: a Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Thomayerova nemocnice, Praha, Česká republika b II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice, Praha, Česká republika c Mezinárodní centrum klinického výzkumu, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny, Brno, Česká republika d III. interní klinika – nefrologická, revmatologická a endokrinologická, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc, Olomouc, Česká republika e II. interní klinika, Lékařská fakulta Plzeň, Univerzita Karlova v Praze a Fakultní nemocnice Plzeň, Plzeň, Česká republika ČESKÁ KARDIOLOGICKÁ SPOLEČNOST THE CZECH SOCIETY OF CARDIOLOGY
795 citations
••
TL;DR: Emergency echocardiography recommendations from the European Association of Cardiovascular Imaging recommendations.
Abstract: Emergency echocardiography : the European Association of Cardiovascular Imaging recommendations
158 citations
••
73 citations
••
TL;DR: A Servicio de Neumología, Hospital de Cruces, Bilbao, España, and a Servicio of Medicina Interna, Hospital Germans Trias I Pujol, Badalona, Spain.
Abstract: a Servicio de Neumologia, Hospital de Cruces, Bilbao, Espana b Servicio de Medicina Interna, Hospital Germans Trias I Pujol, Badalona, Espana c Servicio de Medicina Interna, Hospital Universitario de Gerona Dr. Josep Trueta, Gerona, Espana d Servicio de Hematologia, Hospital Universitario de Bellvitge, Barcelona, Espana e Servicio de Hematologia, Clinica Universitaria de Navarra, Pamplona, Espana f Servicio de Cardiologia, Hospital Doce de Octubre, Madrid, Espana g Servicio de Cardiologia, Hospital Ramon y Cajal, IRYCIS, Madrid, Espana h Servicio de Urgencias, Hospital Clinic, Barcelona, Espana i Servicio de Urgencias, Hospital Clinico San Carlos, Madrid, Espana j Servicio de Angiologia y Cirugia Vascular, Hospital Universitario de Bellvitge, Barcelona, Espana k Servicio de Angiologia y Cirugia Vascular, Hospital Clinico Universitario, Salamanca, Espana l Servicio de Neumologia, Hospital Ramon y Cajal, IRYCIS, Madrid, Espana
69 citations
••
TL;DR: 3DCDE is an accurate and highly reproducible diagnostic tool for estimating CAR severity and has the best agreement with the CMR determined CAR severity.
49 citations
••
TL;DR: TAVI significantly improves symptoms and QoL in patients with severe AS and high surgical risk, and patients with PVD might be expected to have a less impressive improvement inQoL after TAVI.
••
TL;DR: Guidelines on the management of valvular heart disease (version 2012) of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery.
Abstract: Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
••
TL;DR: This is the first reported use of insulin particles as contrast agents for ultrasound, and findings indicate that insulin aggregates provide clear ultrasound contrast in liquid environments.
••
TL;DR: Home respiratory polygraphy is a less costly alternative than polysomnography for the diagnosis and therapeutic decision making for patients with suspected obstructive sleep apnea.
Abstract: Rationale Home respiratory polygraphy (HRP) may be a cost-effective alternative to polysomnography (PSG) for diagnosis and treatment election in patients with high clinical probability of obstructive sleep apnea (OSA), but there is conflicting evidence on its use for a wider spectrum of patients. Objectives To determine the efficacy and cost of OSA management (diagnosis and therapeutic decision making) using (1) PSG for all patients (PSG arm); (2) HRP for all patients (HRP arm); and (3) HRP for a subsample of patients with high clinical probability of being treated with continuous positive airway pressure (CPAP) and PSG for the remainder (elective HRP arm). Methods Multicentric study of 366 patients with intermediate-high clinical probability of OSA, randomly subjected to HRP and PSG. We explored the diagnostic and therapeutic decision agreements between the PSG and both HRP arms for several HRP cutoff points and calculated costs for equal diagnostic and/or therapeutic decision efficacy. Results For equal diagnostic and therapeutic decision efficacy, PSG arm costs were 18% higher than HRP arm costs and 20% higher than elective HRP arm costs. HRP arm costs tended to be lower than elective HRP arm costs, and both tended to be lower than PSG arm costs if patient costs were omitted. Conclusion Home respiratory polygraphy is a less costly alternative than polysomnography for the diagnosis and therapeutic decision making for patients with suspected obstructive sleep apnea. We found no advantage in cost terms, however, in using home respiratory polygraphy for all patients or home respiratory polygraphy for the most symptomatic patients and polysomnography for the rest.
••
TL;DR: There was a clear dissociation between cardiovascular risk scoring and the presence of atherosclerosis, because 1 of 4 study participants at low-to-intermediate cardiovascular risk had carotid Atherosclerosis.
Abstract: A B S T R A C T Introduction and objectives: Detection of carotid atherosclerosis might help to better identify individuals susceptible to cardiovascular events. We aimed to quantify the number of participants with carotid atherosclerosis and low-to-intermediate cardiovascular risk according to the traditional risk factor scoring, and therefore with an elevated risk of cardiovascular events. Methods: Cross-sectional, observational study performed during a cardiovascular screening program. From a total of 3778 volunteers, low-to-intermediate cardiovascular risk individuals (N=2354) were identified and studied. Physical examination, blood test, and carotid ultrasound followed standard procedures. Common, bulb, and internal carotid arteries were examined and common carotid intima- media thickness was measured. SCORE risk value was calculated for all participants. Univariate and multivariate statistical analysis was performed. Results: Mean age of participants was 58.9 (15) years, 43.8% were men, 23.7% had hypertension, and 20.5% had hypercholesterolemia. The mean SCORE value was 1.47 (1.4). Both carotid intima-media thickness and the prevalence of carotid plaques increased steadily and significantly (P<.005) as advanced decades of life were analyzed. Variables significantly related with the presence of carotid atherosclerosis were age, male sex, and systolic blood pressure. Interestingly, 592 (25.1%) individuals were reclassified to a higher risk due to the presence of carotid atherosclerosis. Conclusions: There was a clear dissociation between cardiovascular risk scoring and the presence of atherosclerosis, because 1 of 4 study participants at low-to-intermediate cardiovascular risk had carotid atherosclerosis.
••
TL;DR: The optimal noninvasive parameters and methodology in a given ischemic substrate that best predicts the impact of an intervention on adverse morphological ventricular remodeling and functional recovery and the relative predictive value of each of these parameters will be determined by DOPPLER-CIP.
Abstract: Objectives. DOPPLER-CIP aims to determine the optimal noninvasive parameters (myocardial function, perfusion, ventricular blood flow, cell integrity) and methodology (ergometry, echocardiography, scintigraphy, MRI) in a given ischemic substrate that best predicts the impact of an intervention (or the lack thereof) on adverse morphological ventricular remodeling and functional recovery. Moreover, the relative predictive value of each of these parameters, in respect to the cost of extracting this information in order to enable optimization of cost-effectiveness for improved health care, will be determined by this project. Design. DOPPLER-CIP is a multi-center registry study. All patients with ischemic heart disease included in this study undergo at least two noninvasive stress imaging examinations at baseline. The presence/or absence of left ventricular (LV) remodeling will be assessed after a follow-up of 2 years, during which all cardiac events will be registered. Results. 676 patients were includ...
••
TL;DR: Un estudio transversal y observacional llevado a cabo by the Fundacion Espanola del Corazon, en un programa de cribado poblacional cuantificar a los sujetos con riesgo cardiovascular bajo-intermedio segun las formulas basadas en factores de riedgo tradicionales que presentan ateromatosis carotidea.
Abstract: Resumen Introduccion y objetivos Detectar la ateromatosis carotidea puede ser util para mejorar la identificacion de individuos susceptibles de padecer eventos cardiovasculares. Por ello, el objetivo de este estudio es cuantificar a los sujetos con riesgo cardiovascular bajo-intermedio segun las formulas basadas en factores de riesgo tradicionales que presentan ateromatosis carotidea y, por lo tanto, tienen un riesgo alto de eventos cardiovasculares. Metodos Se trata de un estudio transversal y observacional llevado a cabo por la Fundacion Espanola del Corazon, en un programa de cribado poblacional. De los 3.778 voluntarios, se identifico y estudio a los que presentaban riesgo bajo-intermedio (n = 2.354). Se aplicaron los procedimientos estandar de examen fisico y analisis de sangre. Se examinaron mediante ecografia las arterias carotidas comun, bulbo e interna de ambos lados, para identificar la presencia de placa y se midio el grosor intima-media en la carotida comun. Se calculo el riesgo cardiovascular segun la formula SCORE. Se realizo analisis estadistico bivariable y multivariable de los datos obtenidos. Resultados La media de edad de los participantes era 58,9 ± 15 anos y el 43,8% eran varones. El 23,7% presentaba hipertension y el 20,5%, hipercolesterolemia. La media de riesgo segun la formula SCORE fue 1,47 ± 1,4. Tanto el grosor intima-media como la prevalencia de placa carotidea aumentaron progresiva y significativamente (p > 0,005) en paralelo con las decadas de la vida. Las variables significativamente relacionadas con la presencia de placa carotidea fueron edad, sexo masculino y presion arterial sistolica. Hay que destacar que se reclasifico a 592 (25,1%) sujetos a riesgo mas elevado debido a la presencia de placa carotidea. Conclusiones Existe una clara disociacion entre la estratificacion del riesgo cardiovascular mediante los factores de riesgo tradicionales y la presencia de placa ateromatosa, ya que 1/4 sujetos con riesgo cardiovascular bajo-intermedio presentaba ateromatosis carotidea.
••
TL;DR: In this article, the authors performed a multicentric, randomized, blinded crossover study to determine the agreement between home respiratory polygraphy (HRP) and polysomnography (PSG) by means of two AHI scoring protocols with or without hyperventilation following flow reduction considered as a surrogate arousal.
Abstract: RATIONALE Respiratory polygraphy is an accepted alternative to polysomnography (PSG) for sleep apnea/hypopnea syndrome (SAHS) diagnosis, although it underestimates the apnea-hypopnea index (AHI) because respiratory polygraphy cannot identify arousals. OBJECTIVES We performed a multicentric, randomized, blinded crossover study to determine the agreement between home respiratory polygraphy (HRP) and PSG, and between simultaneous respiratory polygraphy (respiratory polygraphy with PSG) (SimultRP) and PSG by means of 2 AHI scoring protocols with or without hyperventilation following flow reduction considered as a surrogate arousal. METHODS We included suspected SAHS patients from 8 hospitals. They were assigned to home and hospital protocols at random. We determined the agreement between respiratory polygraphy AHI and PSG AHI scorings using Bland and Altman plots and diagnostic agreement using receiver operating characteristic (ROC) curves. The agreement in therapeutic decisions (continuous positive airway pressure treatment or not) between HRP and PSG scorings was done with likelihood ratios and post-test probability calculations. RESULTS Of 366 randomized patients, 342 completed the protocol. AHI from HRP scorings (with and without surrogate arousal) had similar agreement with PSG. AHI from SimultRP with surrogate arousal scoring had better agreement with PSG than AHI from SimultRP without surrogate arousal. HRP with surrogate arousal scoring had slightly worse ROC curves than HRP without surrogate arousal, and the opposite was true for SimultRP scorings. HRP with surrogate arousal showed slightly better agreement with PSG in therapeutic decisions than for HRP without surrogate arousal. CONCLUSION Incorporating a surrogate arousal measure into HRP did not substantially increase its agreement with PSG when compared with the usual procedure (HRP without surrogate arousal).
••
TL;DR: CS can be used as a "gatekeeper" to CTCA in patients with chest pain and should be referred to invasive coronary angiography, avoiding the repeated exposure to ionizing radiation and iodinated contrast.
••
TL;DR: Autores/Membros do Grupo de Trabalho: Joep Perk (Presidente) (Suécia)*, Guy De Backer1 (Bélgica), Helmut Gohlke1 (Alemanha), Ian Graham1 (Irlanda), Zeljko Reiner2 (Croácia), W.M. Scholte Op Reimer1 (Países Baixos).
Abstract: Autores/Membros do Grupo de Trabalho: Joep Perk (Presidente) (Suécia)*, Guy De Backer1 (Bélgica), Helmut Gohlke1 (Alemanha), Ian Graham1 (Irlanda), Zeljko Reiner2 (Croácia), W.M. Monique Verschuren1 (Países Baixos), Christian Albus3 (Alemanha), Pascale Benlian1 (França), Gudrun Boysen4 (Dinamarca), Renata Cifkova5 (República Checa), Christi Deaton1 (RU), Shah Ebrahim1 (RU), Miles Fisher6 (RU), Giuseppe Germano1 (Itália), Richard Hobbs1,7 (RU), Arno Hoes7 (Países Baixos), Sehnaz Karadeniz8 (Turquia), Alessandro Mezzani1 (Itália), Eva Prescott1 (Dinamarca), Lars Ryden1 (Suécia), Martin Scherer7 (Alemanha), Mikko Syvänne9 (Finlândia), Wilma J.M. Scholte Op Reimer1 (Países Baixos), Christiaan Vrints1 (Bélgica), David Wood1 (RU), Jose Luis Zamorano1 (Espanha), Faiez Zannad1 (França).
•
03 Oct 2013
TL;DR: This chapter discusses the application of Contrast Echocardiography in the Assessment of Patients with Chronic Coronary Artery Disease and the therapeutic application of Ultrasound Contrast Agents.
Abstract: 1. The Physiological Basis of Coronary Circulation 2. Microbubbles: Basic Principles 3. Organization of the Echocardiography Contrast Laboratory: Tips and Tricks 4. Quantification Methods in Contrast Echocardiography 5. Clinical Application of Quantitative Analysis in Myocardial Contrast Echocardiography . Contrast Echocardiography for Left Ventricular Opacification 7. Coronary Flow Reserve and Myocardial Contrast Echocardiography 8. Myocardial Contrast Echocardiography in the Assessment of Patients with Chronic Coronary Artery Disease 9. Myocardial Viability: Comparison with Other Imaging Techniques 10. Myocardial Contrast Echocardiography and Inflammatory Response 11. Myocardial Perfusion Imaging During Stress Using Contrast Echocardiography 12. Myocardial Contrast Echocardiography in Acute Myocardial Infarction 13. Can Echocardiography Provide Combined Assessment of Left Ventricular Function and Myocardial Perfusion? 14. From a Toy with Lots of Potential to a Useful Clinical Tool: The Oxford Way of Doing Contrast Echocardiography 15. Clinical Application of Contrast Echocardiography in Critically Ill Patients 16. Therapeutic Application of Ultrasound Contrast Agents.
••
TL;DR: Las guías originales traducidas al castellano se adjunta en un documento en el que se realiza una revisión crítica1 elaborado por un grupo de expertos coordinado por el CGPC (Comité de Guías de Práctica Clínica).
Abstract: Desde el año 2011, la Sociedad Española de Cardiología (SEC) ha establecido un marco de actuación con respecto a las guías de la Sociedad Europea de Cardiología en el que, junto a la publicación de las guías originales traducidas al castellano, se adjunta un documento en el que se realiza una revisión crítica1 elaborado por un grupo de expertos coordinado por el CGPC (Comité de Guías de Práctica Clínica).
••
••
TL;DR: A proactive, multifactorial approach to cardiovascular management based on low-dose SPAA led to statistically significant improvements in calculated 10 year CHD risk versus physician’s UC, comparable to that reported in the full CRUCIAL trial.
Abstract: Objective:A proactive, multifactorial intervention strategy incorporating single-pill amlodipine/atorvastatin (SPAA) (5–10/10 mg up-titrated to 5–10/20 mg, where approved) is more effective than physician’s usual care (UC) for reducing calculated 10 year coronary heart disease (CHD) risk, in patients with hypertension and additional risk factors (CRUCIAL trial: Curr Med Res Opin 2011;27:821--33). As SPAA combinations containing atorvastatin 20 mg are not approved in some countries, this post hoc analysis investigated the efficacy and safety of a proactive intervention strategy incorporating low-dose SPAA (5/10 or 10/10 mg) only (low-dose PI) versus UC.Methods:Of 1461 CRUCIAL participants (35–79 years; hypertension and ≥3 additional risk factors; no CHD; total cholesterol ≤6.5 mmol/L), 105 were prescribed SPAA containing 20 mg atorvastatin and excluded. The primary endpoint was difference between treatment arms in Framingham 10 year CHD risk after 52 weeks; secondary assessments included difference...
••
TL;DR: The ability to orientate a structure from the axial direction of the beam allows new perspectives of the valvular structures, on its face view (‘surgeon's view’) and on its ventricular view, providing a better understanding of the morphology and spatial relation among the intracardiac structures.
Abstract: In the last decade three dimensional echocardiography (3DE) technology has evolved significantly, and the advance of matrix transducers has made its use commonplace in daily clinical practice.1 Currently, it is possible to acquire real-time 3DE images for appropriate visualisation of valvular anatomy and proper quantification of valvular heart disease (VHD). However, 3DE quality depends of a number of factors, including the intrinsic quality of the ultrasound images, the number of heart beats used to reconstruct each 3DE image, and the ability to limit motion artefacts with adequate electrocardiographic and respiratory gating.2 The latter is particularly challenging when using systems requiring electrocardiographically triggered multiple heartbeats for volume rendering analysis. The acquisition of 3DE images can be performed in most ultrasound systems using the ‘live’ mode, by one single heartbeat, ‘full volume’ mode, composed of gated subvolumes, and ‘3D zoom’, ideally with the ultrasound beam aligned perpendicular to the structure under investigation. The decision is dependent on the target structure of the study and the balance between frame rate, volume size, and image resolution, as the improvement of one item is reliant on the other two.1 For the study of VHD the ‘3D zoom’ and ‘live’ modes are the most conventionally used, giving priority to frame rate and imaging resolution.
At the present time 3DE complements 2DE and it is incorporated into clinical practice in numerous centres worldwide. It is already recognised as an important clinical tool, and has been shown to be superior to 2D echocardiography in a variety of VHD scenarios. The ability to orientate a structure from the axial direction of the beam allows new perspectives of the valvular structures, on its face view (‘surgeon's view’) and on its ventricular view, providing a better understanding of the morphology and spatial relation among the intracardiac structures. This …
••
TL;DR: Autores/Miembros del Grupo de Trabajo: Alec Vahanian (Coordinador) (Francia)*, Ottavio Alfieri (CoORDinador)* (Italia), Felicita Andreotti (It Italy), Manuel J. Antunes (Portugal), Gonzalo Baron-Esquivias (Espana), Helmut Baumgartner (Alemania), Michael Andrew Borger ( Alemania)
Abstract: Autores/Miembros del Grupo de Trabajo: Alec Vahanian (Coordinador) (Francia)*, Ottavio Alfieri (Coordinador)* (Italia), Felicita Andreotti (Italia), Manuel J. Antunes (Portugal), Gonzalo Baron-Esquivias (Espana), Helmut Baumgartner (Alemania), Michael Andrew Borger (Alemania), Thierry P. Carrel (Suiza), Michele De Bonis (Italia), Arturo Evangelista (Espana), Volkmar Falk (Suiza), Bernard Iung (Francia), Patrizio Lancellotti (Belgica), Luc Pierard (Belgica), Susanna Price (Reino Unido), Hans-Joachim Schafers (Alemania), Gerhard Schuler (Alemania), Janina Stepinska (Polonia), Karl Swedberg (Suecia), Johanna Takkenberg (Paises Bajos), Ulrich Otto Von Oppell (Reino Unido), Stephan Windecker (Suiza), Jose Luis Zamorano (Espana) y Marian Zembala (Polonia)
••
TL;DR: Three‐dimensional transthoracic echocardiography is proposed as the tool of choice to evaluate TR related to EL, to evaluate the necessity of repositioning the lead if severe regurgitation or tricuspid valve malfunction are demonstrated.
Abstract: Tricuspid regurgitation (TR) produced by endocavitary leads (EL) from permanent pacemakers and implantable cardiac defibrillators is a well-known complication of this procedure. The EL may damage or interfere with tricuspid valve function causing mechanical interference of the valve leaflets leading to incomplete valve closure. It is important to recognize this mechanical complication because it could be corrected by repositioning the lead. In this case report we demonstrate how three-dimensional transthoracic echocardiography permits to obtaining an en face view, which allows simultaneous visualization of the 3 moving leaflets during the cardiac cycle, their attachment to the tricuspid annulus and the pattern of leaflet coaptation. Thus, we propose three-dimensional transthoracic echocardiography as the tool of choice to evaluate TR related to EL, to evaluate the necessity of repositioning the lead if severe regurgitation or tricuspid valve malfunction are demonstrated.
••
TL;DR: Non-invasive mitral and aortic valve evaluation is important in clinical cardiology, not only in valvular heart disease diagnosis but also, and more important, in the selection of best therapeutic approach for each patient.
Abstract: Non-invasive mitral and aortic valve evaluation is important in clinical cardiology. Acquired pathology contributes to high morbidity and mortality. Technical developments, both in surgery and in interventional cardiology, have contributed to the increase in the type and number of treatment procedures. Older patients, sicker patients, and more complex abnormalities are now available for treatment. In this context, non-invasive imaging plays a crucial role not only in valvular heart disease diagnosis but also, and more important, in the selection of best therapeutic approach for each patient.
Aortic and mitral valve are anchored to the fibrous skeleton of the heart. They are in close proximity through the mitro-aortic continuity and share the left and right fibrous trigones. They both are conformed by the annulus, leaflets, and tendineous cords (mitral valve). The left ventricle (LV) plays a key role in the physiology of both valves that far from being passive elements have their own intrinsic function. Both the mitral annulus (MA) and the aortic annulus (AA) with a pre-determined shape undergo anatomical changes along the cardiac cycle that contributes to the function of the valve itself.
For years, research …
••
TL;DR: The PMI strategy based on the inclusion of SPAA in the treatment regimen is more effective than UC in reducing calculated CHD risk and may be considered as the treatment of choice in younger and older hypertensive patients with additional cardiovascular risk factors.
Abstract: Objective:To compare the reduction in calculated Framingham 10 year coronary heart disease (CHD) risk after 52 weeks’ intervention with a proactive multifactorial intervention (PMI) strategy (based on single-pill amlodipine/atorvastatin [SPAA]) versus continuing usual care (UC) (based on investigators' best clinical judgment) among younger (<65 years) and older (≥65 years) patients.Research design and methods:Sub-analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. Eligible patients had hypertension and ≥3 cardiovascular risk factors.Main outcome measure:Treatment-related reduction in calculated Framingham 10 year CHD risk between baseline and Week 52 in younger and older patients.Results:Nine hundred patients (63.5%) were <65 years (mean age 54.2 years, 57.4% men) and 517 patients (36.5%) were ≥65 years (mean age 70.5 years, 42.7% men). Younger patients had lower mean baseline CHD risk versus older patients (17.1% vs. 22.6%). A greate...